Literature DB >> 28417192

Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Arianna Sartori1, Mohammad Abdoli2, Mark S Freedman2.   

Abstract

Benign multiple sclerosis (MS) is a discussed clinical entity, with variable reported prevalence (6-64%) requiring at least 5-10 years of clinical observation. Moreover, many benign patients progress with time becoming no longer benign (NLB). The objective of this study is to compare benign MS patients (EDSS ≤3, 10 years from disease onset) who still fulfilled the definition at 20 years to those NLB. In our retrospective study based on Ottawa Hospital MS Clinic database, 175 benign patients fulfilled the inclusion criteria (clinically definite MS, EDSS ≤3 at 10 years, disease onset from 1983 to 1993, and clinical assessments performed at 10 ± 1 and 20 ± 1 years from onset). Out of the identified patients, 66.3% remained benign at 20 years; however, by changing the definition for benign to EDSS ≤2 or ≤1 at 10 years, they increased to 71.9 and 81.6%, respectively. Female sex, EDSS ≤1 at 10 years, and a pure sensory onset were associated with a benign course, while a pure motor onset with an NLB condition. According to multivariate analysis, an EDSS ≤2 at 10 years predicted a long-term benign course. Our study questions the current definition of "benign" MS, suggesting a more stringent EDSS cutoff at 10 years to predict long-term benign prognosis.

Entities:  

Keywords:  Benign course; Disease modifying drugs; Long-term follow-up; Multiple sclerosis; Natural history; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28417192     DOI: 10.1007/s00415-017-8487-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

1.  The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy.

Authors:  P Perini; C Tagliaferri; M Belloni; G Biasi; P Gallo
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

2.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

Review 3.  Benign course in multiple sclerosis: a review.

Authors:  G S M Ramsaransing; J De Keyser
Journal:  Acta Neurol Scand       Date:  2006-06       Impact factor: 3.209

4.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

5.  Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system.

Authors:  S Poser; J Wikström; H J Bauer
Journal:  J Neurol Sci       Date:  1979-02       Impact factor: 3.181

6.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

7.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

8.  Longitudinal follow-up of "benign" multiple sclerosis at 20 years.

Authors:  Ana-Luiza Sayao; Virginia Devonshire; Helen Tremlett
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

9.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  4 in total

1.  The financial contribution of the multiple sclerosis specialist.

Authors:  James N Goldenberg
Journal:  Neurol Clin Pract       Date:  2017-10

2.  How common is truly benign MS in a UK population?

Authors:  Emma Clare Tallantyre; Paula C Major; Michael J Atherton; W Adam Davies; Fady Joseph; Valentina Tomassini; Trevor P Pickersgill; Katharine Elizabeth Harding; Mark Douglas Willis; Mia Winter; Neil P Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-09-03       Impact factor: 10.154

Review 3.  Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation.

Authors:  Simon Thebault; Ronald A Booth; Carolina A Rush; Heather MacLean; Mark S Freedman
Journal:  Front Neurosci       Date:  2021-03-25       Impact factor: 4.677

Review 4.  Serum neurofilament light in MS: The first true blood-based biomarker?

Authors:  Simon Thebault; Gauruv Bose; Ronald Booth; Mark S Freedman
Journal:  Mult Scler       Date:  2021-02-10       Impact factor: 5.855

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.